In 2009, Brayden was cooking noodles when his t-shirt caught fire from the stove element. He received burns to 45 percent of his body.
He was rushed from his home in Dunedin to Middlemore Hospital where he spent three weeks in the intensive care unit until his condition stabilised.
Brayden was then transferred to the burns unit for specialist treatment before spending time in the Kidz First unit and finally to Christchurch Hospital before he returned home.
In the two years following his accident, Brayden spent more time in hospital than he did at home.
To date, he has undergone more than 20 operations and has many more ahead of him.
Despite his frequent stays in hospital, Brayden’s family has worked hard to ensure his life carried on as normal. Brayden loves playing both tackle and Rippa Rugby, drawing, building with his Lego and playing on his guitar.
Burn injury is a leading cause of injury to children in New Zealand. Every year in New Zealand, approximately 475 children under 15 years are admitted to hospital as a result of burns or scalds. 80% of these are five years or under.
For major burn injuries, treatment is still slow, painful and fraught with risk – and even successful treatment carries long-term side effects such as wound contracture. Current best practice at the National Burn Centre has reduced the mortality for a 50% burn, but successful treatment for a major burn injury still involves grueling rounds of surgery.
Cure Kids-funded researcher, Professor Rod Dunbar, from the University of Auckland, has discovered a technique for growing full-thickness human skin in the lab. Using skin tissue obtained from patients undergoing elective surgeries, they’ve managed to use these cells to grow the human skin in the lab.
This has great potential to be transformative for the practice of treating burns. Children and adults, like Brayden, would no longer be subjected to painful and invasive skin grafts and obtaining healthy skin from unburnt parts of the body would no longer be an issue.
While not yet available for human use, the research team are confident that human trials could commence as early as 2017.